PCM
ZYNE

Portolan Capital Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Portolan Capital Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-434,768
Closed -$1.67M – 149
2020
Q1 		$1.67M Sell
434,768
-1,494
-0.3% -$6.94K 0.25% 95
2019
Q4 		$2.63M Sell
436,262
-341,031
-44% -$2.33M 0.27% 76
2019
Q3 		$5.88M Buy
777,293
+150,557
+24% +$1.7M 0.66% 48
2019
Q2 		$8.49M Buy
+626,736
New +$7.24M 0.91% 44

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Portolan Capital Management's ZYNE Position: Q2 2020 in Review

Portolan Capital Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2020, closing a stake of 434,768 shares — an estimated $1.67M sold.

Portolan Capital Management first reported a position in ZYNE in Q2 2019 and held it in 4 quarters. The position peaked at $8.49M in Q2 2019. 74 funds tracked by Wall St. Rank hold ZYNE as of Q2 2020.

  • Portolan Capital Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2020 after selling out during the quarter.
  • Portolan Capital Management sold 434,768 Zynerba Pharmaceuticals, Inc shares in Q2 2020, an estimated $1.67M.
  • Portolan Capital Management first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2019 and held it in 4 quarters.
  • Portolan Capital Management's Zynerba Pharmaceuticals, Inc position peaked at $8.49M in Q2 2019.
  • 74 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2020.

Based on Portolan Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.